Bladder Cancer Treatment in India 2026: TURBT, Cystectomy & Costs for International Patients

Bladder Cancer Treatment in India 2026: TURBT, Cystectomy & Costs for International Patients

Bladder cancer is the 10th most common cancer worldwide, with over 600,000 new cases diagnosed annually. Across Africa, it is increasingly being detected — particularly in countries where schistosomiasis infection (bilharzia) is prevalent, as chronic schistosomal infection of the bladder significantly increases squamous cell carcinoma risk. Tobacco use and occupational chemical exposure are also major contributors.

For African patients diagnosed with bladder cancer, India offers world-class uro-oncology treatment at costs that are 70–85% less than Western countries. This guide covers the full treatment pathway — from initial diagnosis to surgery, chemotherapy, and long-term surveillance — for international patients.

Understanding Bladder Cancer: Types and Staging

Before discussing treatment, it's important to understand that bladder cancer is not a single disease:

By cell type:

• Transitional cell carcinoma (TCC) / Urothelial carcinoma — 90% of cases in most countries; arises from the bladder lining
• Squamous cell carcinoma (SCC) — more common in Africa due to schistosomiasis association; tends to be more aggressive
• Adenocarcinoma — rare, but occurs in bladder remnants and urachal tumours

By invasion depth:

• Non-muscle-invasive bladder cancer (NMIBC) — cancer confined to the inner lining (stages Ta, T1, CIS); treated with TURBT and intravesical therapy
• Muscle-invasive bladder cancer (MIBC) — cancer invading the bladder muscle (T2–T4); usually requires radical cystectomy or definitive chemoradiation

Staging determines everything — treatment approach, prognosis, and cost. The majority of bladder cancers (70–75%) are non-muscle-invasive at diagnosis, which is fortunate as these are highly treatable.

TURBT: The Foundation of Bladder Cancer Diagnosis and Treatment

Transurethral resection of bladder tumour (TURBT) is both the primary diagnostic procedure and the first-line treatment for NMIBC. A urologist passes a resectoscope through the urethra and uses electrical current to remove visible tumours from the bladder wall.

What TURBT achieves:

1. Complete removal of visible tumour
2. Accurate pathological staging (grade, depth of invasion)
3. Assessment of muscle invasion
4. Potential cure for low-grade NMIBC

TURBT in India — what to expect:

• Duration: 30–90 minutes under spinal or general anaesthesia
• Hospital stay: 1–3 days
• Catheter: 1–3 days post-procedure
• Return to normal activity: 1–2 weeks
• Cost in India: $2,000–$4,000 including hospital stay, anaesthesia, and pathology

For high-risk NMIBC (high-grade T1 or CIS), a second-look TURBT 4–6 weeks after the first is recommended to ensure complete resection. Indian uro-oncology centres routinely perform this protocol.

Intravesical Therapy: BCG and Chemotherapy

After TURBT, intravesical therapy (drugs instilled directly into the bladder) reduces recurrence risk and, in the case of BCG, prevents progression to muscle-invasive disease.

Intravesical BCG (Bacillus Calmette-Guérin):
BCG is a live attenuated bacterial strain that triggers an immune response against cancer cells. It is the most effective intravesical treatment for intermediate and high-risk NMIBC.

Standard protocol: 6 weekly instillations (induction), followed by maintenance instillations for 1–3 years.

Cost in India: $100–$200 per instillation (vs $1,000–$3,000 in the USA). This difference is enormous when you're looking at 27+ instillations over 3 years.

Intravesical chemotherapy:
Mitomycin C or gemcitabine may be used for lower-risk tumours. A single immediate post-TURBT instillation of mitomycin C reduces short-term recurrence risk significantly. Cost: $50–$100 per instillation in India.

Radical Cystectomy for Muscle-Invasive Disease

For MIBC, radical cystectomy — surgical removal of the bladder — is the standard of care in most cases. In men, this typically includes removal of the prostate and seminal vesicles; in women, the uterus, ovaries, and anterior vaginal wall may be included.

Urinary diversion options after cystectomy:

• Ileal conduit — most common; urine drains through a stoma to an external bag
• Neobladder (orthotopic) — a new bladder constructed from bowel; urine passes normally through the urethra
• Indiana pouch — continent reservoir; patient self-catheterises

Approaches in India:

Approach	Description	Cost in India
Open radical cystectomy	Standard approach; well-established	$6,000–$8,000
Laparoscopic cystectomy	Minimally invasive; faster recovery	$7,000–$9,000
Robotic radical cystectomy (da Vinci)	Highest precision; least blood loss	$8,000–$12,000

Robotic radical cystectomy is available at Apollo, Fortis, Kokilaben, and Medanta. India has one of the highest concentrations of da Vinci systems in Asia.

Neoadjuvant and Adjuvant Chemotherapy

For MIBC, neoadjuvant (pre-surgery) cisplatin-based chemotherapy (MVAC or gemcitabine+cisplatin) is recommended in fit patients — it improves 5-year survival by 5–8 percentage points.

In India, gemcitabine+cisplatin (GC) regimen costs approximately:

• Gemcitabine per cycle: $50–$150 (generic)
• Cisplatin per cycle: $20–$60 (generic)
• Complete 4-cycle neoadjuvant course: $500–$1,500

Compare this to $10,000–$20,000 for the same regimen in the USA.

Bladder-Preserving Trimodality Therapy

For selected patients who are unfit for or decline cystectomy, trimodality therapy (TMT) offers bladder preservation:

1. Maximal TURBT
2. Concurrent cisplatin-based chemotherapy
3. External beam radiotherapy (60–64 Gy)

5-year cancer-specific survival with TMT is 50–65% for T2 disease, approaching cystectomy outcomes in carefully selected patients. Indian radiation oncology centres with IMRT/VMAT technology can deliver precise bladder radiotherapy while sparing surrounding structures.

Radiotherapy cost in India: $2,500–$5,000 for a full course (vs $25,000–$50,000 in the USA).

India's Top Uro-Oncology Centres

Rajiv Gandhi Cancer Institute (RGCI), Delhi — One of India's most specialised cancer hospitals with a dedicated uro-oncology programme. High TURBT and cystectomy volumes, excellent pathology services.

Tata Memorial Hospital, Mumbai — India's premier government cancer centre, originally established with international collaboration. World-class outcomes data; affordable pricing; some charitable care available.

Apollo Proton Cancer Centre, Chennai — Advanced technology including proton therapy. Comprehensive bladder cancer programme.

Fortis Memorial Research Institute, Gurgaon — Robotic surgery centre with strong urology programme; experienced with international patients.

Kokilaben Dhirubhai Ambani Hospital, Mumbai — State-of-the-art facility with multi-disciplinary tumour board for bladder cancer cases.

Surveillance After Treatment

Bladder cancer has one of the highest recurrence rates of any cancer — up to 70% of NMIBC recurs within 5 years. Surveillance cystoscopy (looking inside the bladder with a camera) is mandatory:

• First 2 years: every 3 months
• Years 3–5: every 6 months
• After 5 years: annually (for high-risk tumours)

For patients who return to Africa after treatment in India, Arodya helps establish a surveillance plan with your local urologist, with annual review trips to India if needed. Learn about post-treatment follow-up planning.

Schistosomiasis-Related Bladder Cancer: A Note for African Patients

In Egypt, Sudan, and parts of East and West Africa, schistosomiasis infection causes chronic bladder inflammation that can lead to squamous cell carcinoma. SCC behaves differently from TCC:

• Often presents at later stage
• More aggressive course
• Different chemotherapy sensitivity (cisplatin-based still used)
• Cystectomy often appropriate even for some T1 SCC

Indian uro-oncologists are experienced with SCC bladder cancer, including in African patients. If your diagnosis is SCC, ensure your treating team is aware of the schistosomiasis history. Serological testing for active infection and treatment with praziquantel should also be considered before definitive cancer surgery.

Planning Your Bladder Cancer Treatment Trip

To start your journey, get a consultation with Arodya. Share:

• Cystoscopy and TURBT pathology reports
• CT urogram or staging CT/MRI
• Urine cytology results
• Any prior treatments

We will match you with a uro-oncologist specialising in your specific tumour type, provide a cost estimate for the complete treatment pathway, and manage your logistics from arrival to departure.

Bladder cancer is treatable, especially when caught early. India's uro-oncology expertise, generic drug access, and advanced surgical technology make it the world's most cost-effective destination for this treatment. Don't delay — start your assessment today.